• Briacell signed a non-binding MoU with Netherlands-based Uneedle to support microneedle delivery for intradermal administration of Bria-IMT.
• Collaboration targets scale-up of Uneedle devices to commercial quantities, contingent on regulatory approvals for Bria-IMT.
• Uneedle’s microneedle technology is already used to administer Bria-IMT in Briacell’s pivotal Phase 3 metastatic breast cancer trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606250730PRIMZONEFULLFEED9752304) on June 25, 2026, and is solely responsible for the information contained therein.